CA3246901A1 - Modulateurs de traduction d'acide ribonucléique messager (arnm) c-myc et leurs utilisations dans le traitement du cancer - Google Patents

Modulateurs de traduction d'acide ribonucléique messager (arnm) c-myc et leurs utilisations dans le traitement du cancer

Info

Publication number
CA3246901A1
CA3246901A1 CA3246901A CA3246901A CA3246901A1 CA 3246901 A1 CA3246901 A1 CA 3246901A1 CA 3246901 A CA3246901 A CA 3246901A CA 3246901 A CA3246901 A CA 3246901A CA 3246901 A1 CA3246901 A1 CA 3246901A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
phenyl
carboxamide
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246901A
Other languages
English (en)
Inventor
Boaz Inbal
Aviad MANDABI
Stephen David Penrose
Luba SIMHAEV ISCHAKOV
Iris Alroy
Rina WASSERMANN
Yoni SHEINBERGER
Yaode Wang
Haitang Li
Lothar Willms
Scott Alexander SADLER
Shuyu Chu
Original Assignee
Anima Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/856,998 external-priority patent/US20220370431A1/en
Application filed by Anima Biotech Inc filed Critical Anima Biotech Inc
Publication of CA3246901A1 publication Critical patent/CA3246901A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"Il est décrit de nouveaux modulateurs de traduction d'ARNm c-myc, une composition et des méthodes de préparation de ceux-ci, ainsi que leurs utilisations dans le traitement du cancer."
CA3246901A 2022-07-03 2023-07-02 Modulateurs de traduction d'acide ribonucléique messager (arnm) c-myc et leurs utilisations dans le traitement du cancer Pending CA3246901A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263358134P 2022-07-03 2022-07-03
US63/358,134 2022-07-03
US17/856,998 US20220370431A1 (en) 2021-01-05 2022-07-03 C-myc mrna translation modulators and uses thereof in the treatment of cancer
US17/856,998 2022-07-03
PCT/US2023/026827 WO2024010761A1 (fr) 2022-07-03 2023-07-02 Modulateurs de traduction d'arnm c-myc et leurs utilisations dans le traitement du cancer

Publications (1)

Publication Number Publication Date
CA3246901A1 true CA3246901A1 (fr) 2024-01-11

Family

ID=89454000

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3246917A Pending CA3246917A1 (fr) 2022-07-03 2023-07-02 Modulateurs de traduction d'acide ribonucléique messager (arnm) c-myc et leurs utilisations dans le traitement du cancer
CA3246901A Pending CA3246901A1 (fr) 2022-07-03 2023-07-02 Modulateurs de traduction d'acide ribonucléique messager (arnm) c-myc et leurs utilisations dans le traitement du cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3246917A Pending CA3246917A1 (fr) 2022-07-03 2023-07-02 Modulateurs de traduction d'acide ribonucléique messager (arnm) c-myc et leurs utilisations dans le traitement du cancer

Country Status (7)

Country Link
EP (2) EP4547672A1 (fr)
JP (2) JP2025523367A (fr)
CN (2) CN119255997A (fr)
AU (2) AU2023305002A1 (fr)
CA (2) CA3246917A1 (fr)
IL (2) IL316809A (fr)
WO (2) WO2024010761A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
KR101449057B1 (ko) * 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
IL279972A (en) * 2021-01-05 2022-08-01 Anima Biotech Inc Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment

Also Published As

Publication number Publication date
CN119255997A (zh) 2025-01-03
IL316809A (en) 2025-01-01
IL316805A (en) 2025-01-01
AU2023305002A1 (en) 2024-11-14
AU2023304182A1 (en) 2024-11-14
JP2025521719A (ja) 2025-07-10
CA3246917A1 (fr) 2024-01-11
EP4547671A1 (fr) 2025-05-07
WO2024010762A1 (fr) 2024-01-11
EP4547672A1 (fr) 2025-05-07
CN119233976A (zh) 2024-12-31
WO2024010761A1 (fr) 2024-01-11
JP2025523367A (ja) 2025-07-23

Similar Documents

Publication Publication Date Title
AU2019204539B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2015261812B2 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
US20060074102A1 (en) Kinase inhibitors as therapeutic agents
US11142526B2 (en) Spirocycle compounds and methods of making and using same
US20230150980A1 (en) Collagen 1 translation inhibitors and methods of use thereof
US20230212131A1 (en) Collagen 1 translation inhibitors and methods of use thereof
US20170015654A1 (en) Pyridazine compound
AU2012267622A1 (en) Metabotropic glutamate receptor 5 modulators and methods of use thereof
JP2022517085A (ja) ハロゲン化アリルアミン系化合物及びその適用
US20220370431A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
EP4463452B1 (fr) Modulateurs de traduction d'arnm c-myc et leurs utilisations dans le traitement du cancer
CA3246901A1 (fr) Modulateurs de traduction d'acide ribonucléique messager (arnm) c-myc et leurs utilisations dans le traitement du cancer
WO2023225244A1 (fr) Composés hétérocycliques pour le traitement de la maladie de huntington
US12404283B2 (en) c-MYC mRNA translation modulators and uses thereof in the treatment of cancer
US20250353862A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
JP2025526462A (ja) ハンチントン病を治療するための化合物

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240926

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241112

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241112

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520